Open access
Open access
Powered by Google Translator Translator

Oncology - Urological

Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update

21 Feb, 2021 | 21:47h | UTC

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update – Journal of Clinical Oncology

 


Preliminary study suggests there may be a role for prostate cancer screening with magnetic resonance imaging

16 Feb, 2021 | 01:50h | UTC

Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study – JAMA Oncology

Commentaries: Short MRI Protocol Could Be Alternative for Prostate Cancer Follow-Up – Diagnostic Imaging AND Short MRI exam shows promise for prostate cancer screening follow-up – AuntMinnie (free registration required)

 

Commentary on Twitter

 


RCT: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

15 Feb, 2021 | 00:36h | UTC

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Immunotherapy – targeted drug combination improves survival in advanced kidney cancer – Dana-Farber Cancer Institute

 

Commentary on Twitter

 


RCT: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

15 Feb, 2021 | 00:34h | UTC

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: 2021 Genitourinary Cancers Symposium: Enfortumab Vedotin-ejfv Prolongs Survival in Patients With Metastatic Urothelial Carcinoma – The ASCO Post

 


RCT: A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma

15 Feb, 2021 | 00:32h | UTC

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Cabozantinib most effective treatment for metastatic papillary kidney cancer – MedicalXpress

 


Long-term data: No difference in cardiovascular mortality or morbidity with transdermal estradiol vs. LHRH agonists for androgen suppression in prostate cancer

15 Feb, 2021 | 00:31h | UTC

Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme – The Lancet (link to abstract – $ for full-text)

 


RCT: Radiopharmaceutical therapy vs. cabazitaxel in patients with metastatic castration-resistant prostate cancer

15 Feb, 2021 | 00:29h | UTC

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Radionuclide Tx Wins in Third-Line Metastatic CRPC – MedPage Today

 


RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer

5 Feb, 2021 | 01:27h | UTC

Comparison of Multiparametric Magnetic Resonance Imaging–Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial – JAMA Oncology

Commentary: Clinical trial: Using MRI for prostate cancer diagnosis equals or beats current standard – Ontario Institute for Cancer Research AND Another Win for MRI and Targeted Prostate Biopsy – MedPage Today (free registration required)

Related: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis – New England Journal of Medicine (study and commentaries) Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis – European Urology AND Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer (studies and commentaries)

 


Stay Updated in Your Specialty

No spam, just news.